New guidelines for treating atrial fibrillation (afib) recommend considering the new oral anticoagulant drugs apixaban (Eliquis), dabigatran (Pradaxa), and rivaroxaban (Xarelto). Compared with warfarin, these drugs are just as effective for preventing a stroke (a serious risk with afib) but are less likely to cause dangerous bleeds in the brain. Other updates include less reliance on aspirin for clot prevention and a newer risk score to better predict a person’s risk of complications from afib.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.